Statistics for Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer
Total visits
| views | |
|---|---|
| Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer | 1 |
Total visits per month
| views | |
|---|---|
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 1 |